Management of stage III non–small-cell lung cancer: ASCO guideline
ME Daly, N Singh, N Ismaila, MB Antonoff… - Journal of Clinical …, 2022 - ascopubs.org
PURPOSE To provide evidence-based recommendations to practicing clinicians on
management of patients with stage III non–small-cell lung cancer (NSCLC). METHODS An …
management of patients with stage III non–small-cell lung cancer (NSCLC). METHODS An …
Revisiting neoadjuvant therapy in non-small-cell lung cancer
Despite the rapidly evolving treatment landscape in advanced non-small-cell lung cancer
(NSCLC), developments in neoadjuvant and adjuvant treatments have been nascent by …
(NSCLC), developments in neoadjuvant and adjuvant treatments have been nascent by …
[HTML][HTML] Perioperative nivolumab and chemotherapy in stage III non–small-cell lung cancer
M Provencio, E Nadal… - … England Journal of …, 2023 - Mass Medical Soc
Background Approximately 20% of patients with non–small-cell lung cancer (NSCLC)
receive a diagnosis of stage III disease. There is no current consensus regarding the most …
receive a diagnosis of stage III disease. There is no current consensus regarding the most …
Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Lung cancer is the leading cause of cancer mortality worldwide with 1.8 million newly
diagnosed cases, or 13% of all cancers diagnosed, in 2012 [1]. The worldwide numbers are …
diagnosed cases, or 13% of all cancers diagnosed, in 2012 [1]. The worldwide numbers are …
Somatic mutations drive distinct imaging phenotypes in lung cancer
Tumors are characterized by somatic mutations that drive biological processes ultimately
reflected in tumor phenotype. With regard to radiographic phenotypes, generally …
reflected in tumor phenotype. With regard to radiographic phenotypes, generally …
MR-guidance in clinical reality: current treatment challenges and future perspectives
Abstract Magnetic Resonance-guided radiotherapy (MRgRT) marks the beginning of a new
era. MR is a versatile and suitable imaging modality for radiotherapy, as it enables direct …
era. MR is a versatile and suitable imaging modality for radiotherapy, as it enables direct …
[HTML][HTML] Recurrence after surgery in patients with NSCLC
H Uramoto, F Tanaka - Translational lung cancer research, 2014 - ncbi.nlm.nih.gov
Surgery remains the only potentially curative modality for early-stage non-small cell lung
cancer (NSCLC) patients and tissue availability is made possible. However, a proportion of …
cancer (NSCLC) patients and tissue availability is made possible. However, a proportion of …
Management of non-small-cell lung cancer: recent developments
Non-small-cell lung cancer is one of the leading causes of deaths from cancer worldwide.
Therefore, improvements in diagnostics and treatments are urgently needed. In this review …
Therefore, improvements in diagnostics and treatments are urgently needed. In this review …
Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate …
MD Hellmann, JE Chaft, WN William, V Rusch… - The lancet …, 2014 - thelancet.com
Improvements in outcomes for patients with resectable lung cancers have plateaued.
Clinical trials of resectable non-small-cell lung cancers with overall survival as the primary …
Clinical trials of resectable non-small-cell lung cancers with overall survival as the primary …
Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial
Background One of the standard options in the treatment of stage IIIA/N2 non-small-cell lung
cancer is neoadjuvant chemotherapy and surgery. We did a randomised trial to investigate …
cancer is neoadjuvant chemotherapy and surgery. We did a randomised trial to investigate …